Why a Planned Reorganization of the FDA Creates Major Challenges

This JAMA Forum discusses the potential downsides of reorganization of the US Food and Drug Administration (FDA), including introducing inefficiencies, and provides examples of past restructuring efforts.

Authors

Scott L. Gottlieb (ORCID: https://orcid.org/0000-0002-9455-3671)
Mark McClellan

Institutions

American Enterprise Institute (US)
Duke Institute for Health Innovation (US)

Publication Details

Journal: JAMA Health Forum
Published: 2025-05-08
DOI: https://doi.org/10.1001/jamahealthforum.2025.2326
Primary Topic: Pharmaceutical Economics and Policy
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Why a Planned Reorganization of the FDA Creates Major Challenges

Scott L. Gottlieb, Mark McClellan

May 8, 2025

JAMA Health Forum

Pharmaceutical Economics and Policy

article

Why a Planned Reorganization of the FDA Creates Major Challenges

Scott L. Gottlieb, Mark McClellan

May 8, 2025article en

Abstract

JAMA Health ForumVol. 6(5)

American Enterprise Institute (US), Duke Institute for Health Innovation (US)

Openalex Percentile: Top 86%

Pharmaceutical Economics and Policy

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Why a Planned Reorganization of the FDA Creates Major Challenges — Scott L. Gottlieb, Mark McClellan · JAMA Health Forum (2025) | TGRS Research Map | TGRS